Vaccines comprising nucleotide sequences encoding bovine herpesvirus type 1 g1, g111 and gIV

Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination and methods of recombinantly producing the subunit antigens or nucleotide sequences employed in the vaccines.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A vaccine composition to prevent or ameliorate the symptoms of disease comprising an isolated nucleotide sequence encoding a polypeptide containing at least one protective determinant of a BHV-1 polypeptide, operably linked to one or more control sequences such that said isolated nucleotide sequence is expressed in a host cell, the polypeptide being selected from the group consisting of gI, wherein said isolated nucleotide sequence comprises the contiguous nucleotide sequence depicted in FIG. 5; gIII, wherein said isolated nucleotide sequence comprises the contiguous nucleotide sequence depicted in FIG. 6; and gIV, wherein said isolated nucleotide sequence comprises the contiguous nucleotide sequence depicted in FIG. 7.

2. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 1.

3. The vaccine composition of claim 1, wherein the nucleotide sequence is the contiguous nucleotide sequence depicted in FIG. 5.

4. The vaccine composition of claim 1, wherein the nucleotide sequence is the contiguous nucleotide sequence depicted in FIG. 6.

5. The vaccine composition of claim 1, wherein the nucleotide sequence is the contiguous nucleotide sequence depicted in FIG. 7.

6. A vaccine composition to prevent or ameliorate the symptoms of disease comprising an isolated nucleotide sequence encoding a polypeptide containing at least one protective determinant of a recombinant BHV-1 glycoprotein, operably linked to one or more control sequences such that said isolated nucleotide sequence is expressed in a host cell, said recombinant BHV-1 glycoprotein selected from the group consisting of BHV-1 gI having an unglycosylated molecular weight of about 105 kDa and encoded by the nucleotide sequence as depicted in FIG. 5; gIII glycoprotein having a molecular weight of about 91 kDa and encoded by the nucleotide sequence as depicted in FIG. 6; and a gIV glycoprotein having a molecular weight of about 71 kDa and encoded by the nucleotide sequence as depicted in FIG. 7.

7. The vaccine composition of claim 6 wherein the BHV-1 glycoprotein is BHV-1 gI glycoprotein having an unglycosylated molecular weight of about 105 kDa and encoded by the nucleotide sequence as depicted in FIG. 5.

8. The vaccine composition of claim 6 wherein the BHV-1 glycoprotein is BHV-1 gIII glycoprotein having a molecular weight of about 91 kDa and encoded by the nucleotide sequence as depicted in FIG. 6.

9. The vaccine composition of claim 6 wherein the BHV-1 glycoprotein is BHV-1 gIV glycoprotein having a molecular weight of about 71 kDa and encoded by the nucleotide sequence as depicted in FIG. 7.

10. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 6.

11. A vaccine composition to prevent or ameliorate the symptoms of disease comprising an isolated nucleotide sequence encoding a polypeptide containing at least one protective determinant of a truncated BHV-1 gIV polypeptide operably linked to one or more control sequences such that said isolated nucleotide sequence is expressed in a host cell, wherein said polypeptide consists of residues 1-355 as depicted in FIG. 5.

12. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim 11.

Referenced Cited
U.S. Patent Documents
4335105 June 15, 1982 Gough
4341784 July 27, 1982 Kaplan et al.
4642333 February 10, 1987 Person
4661349 April 28, 1987 Kino et al.
4680176 July 14, 1987 Beins et al.
4709011 November 24, 1987 Cohen et al.
4724146 February 9, 1988 Kino et al.
5151267 September 29, 1992 Babiuk et al.
5585264 December 17, 1996 Babiuk et al.
Foreign Patent Documents
0362531 April 1990 EPX
1340418 March 1923 GBX
WO 88/02634 April 1988 WOX
8802634 April 1989 WOX
Other references
  • Manickan, E. et al., Crit. Rev. Immunol. 17:139-154, "DNA Vaccines --a modern gimmick or a boon to vaccinology?", 1997. Wolff et al.., Science 247:1465, 1990. Robinson et al., Vaccine 11:975-, 1990. Ulmer et al., Science 254:1745-, 1993. Babiuk et al. (1975) Infect. Immun. 12:958-963. Misra et al. (1981) J. Virol. 40:367-378. van Drunen Littel-van den Hurk et al. (1984) Virology 135:466-479. van Drunen Littel-van den Hurk et al. (1985) Virology 144:216-227. Collins et al. (1984) J. Virol. 52:403-409. Okazaki et al. (1986) Virology 150:260-264. van Drunen Littel-van den Hurk et al. (1985) Virology 144:204-215. van Drunen Littel-van den Hurk et al. (1986) J. Clin. Microbiol. 23:274-282. Okazaki et al. (1987) Arch. Virol. 92:17-26. Mayfield et al. (1983) J. Virol. 47:259-264. Pachl et al. (1987) J. Virol. 61:315-325. Babiuk et al. (1987) Virology 159:57-66. Lupton et al. (1980) Am. J. Vet. Res. 41:383-390. Cox et al., "Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA" J. Virology (1993) 67:5664-5667. Hammerschmidt et al., "Common epitopes of glycoprotein B map within the major DNA-binding proteins of bovine herpesvirus type 2 (BHV-2) and herpes simplex virus type 1 (HVS-1)" Virology (1988) 165:408-418. Lawrence et al., "Map location of the gene for a 130,000-dalton glycoprotein of bovine herpesvirus 1" J. Virol. (1986) 60:405-414. Liang et al., "An in vivo study of a glycoprotein gill-negative bovine herpesvirus 1 (BHV-1) mutant expressing B-galactosidase: evaluation of the role of gill in virus infectivity and its use as a vector for mucosal immunization" Virology (1992) 189:629-639. Misra et al., "Sequence of a bovine herpesvirus type-1 glycoprotein gene that is homologous to the herpes simplex gene for glycoprotein g.beta." Virology (1988) 166:542-549. van Drunen Littel-van den hurk et al., "Synthesis and processing of bovine herpesvirus 1 glycoproteins" J. Virology (1986) 59:401-410. van Drunen Littel-van den Hurk et al., "Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins" Vaccine (1990) 8:358-368. Leary et al., "Recombinant herpesviral proteins produced by cell-free translation provide a novel approach for the mapping of T lymphocyte epitopes" J. Immunol. (1990) 145:718-723. (Medline accession No. 07401317). Leary et al., "Constitutively expressing cell lines that secrete a truncated bovine herpes virus-1 glycoprotein (gpl) stimulates T-lymphocyte responsiveness" Immunology (1992) 76:3673-3672. Palmer et al., "Bovine natural killer-like cell responses against cell lines expressing recombinant bovine herpesvirus type 1 glycoproteins" J. Innumol. (1990) 145:1009-1014. Babiuk et al., "Protection of cattle from bovine herpesvirus type 1 (BHV-1) infection by immunization with individual viral glycoproteins" Virol. (1987) 159:57-66. Collins et al., "Neutralizing determinants defined by monoclonal antibodies on polypeptides specified by bovine herpesvirus 1" J. Virol. (1984) 52:403-409. Fitzpatrick et al., "Expression of bovine herpesvirus 1 glycoproteins gl and glll in transfected murine cells" J. Virol. (1988) 62:4239:4248. Fitzpatrick et al., "Mapping of 10 epitopes on bovine herpesvirus type, glycoproteins gl and glll" Virol. (1990) 176:145-157. Gerber et al., "Local and systemic cellular and antibody immune responses of cattle to infectious bovine rhinotracheitis virus vaccines administered intranasally or intramuscularly" Am. J. Vet. Res. (1978) 39:753-760. Hughes et al., "Functional and topographical analyses of epitopes on bovine herpesvirus type 1 glycoprotein IV" Arch. Virol. (1988) 103:47-60. Jericho et al., "The effect of dose, route and virulence of bovine herpesvirus 1 vaccine on experimental respiratory disease in cattle" Can. J. Com. Med. (1983) 47:133-139. Mayfield et al., "Cloning and cleavage site mapping of DNA from bovine herpesvirus 1 (Cooper Strain)" J. Virol. (1983) 47:259-264. Misra et al., "Proteins specified by bovine herpesvirus 1(Infectious Bovine Rhinotracheitis Virus)" J. Virol. (1981) 40:367-378. Okazaki et al., "Mechanisms of neutralization by monoclonal antibodies to different antigenic sites on the bovine herpesvirus type 1 glycoproteins" Virology (1986) 150:260-264. Pachl et al., "Expression of cell-associated and secreted forms of herpes simplex virus Type 1 glycoprotein gB in mammalian cells" J. Virol. (1987) 61:315-325. Pastoret et al., "Reactivation of temperature-sensitive and non-temperature sensitive infectious bovine rhinotracheitis vaccine virus with dexamethasone" Infect. Immun. (1980) 29:483-488. Tikoo et al., "Molecular cloning, sequencing, and expression of functional bovine herpesvirus 1 glycoprotein gIV in transfected bovine cells" J. Virol. (1990) 64:5132-5142. van Drunen Littel-van den Hurk et al., "Interactions of monoclonal antibodies and bovine herpesvirus type 1 (BHV-1) glycoproteins: characterization of their biochemical and immunological properties" Virology (1984) 135:466-479. van Drunen Littel-van den Hurk et al., "Antigenic and immunogenic characteristics of bovine herpesvirus type-1 glycoproteins GVP 3/9 and GVP 6/11a/16, urified by immunoadsorbent chromatography" Virology (1985) 144:204-215. van Drunen Littel-van den Hurk et al., "Topographical analysis of bovine herpesvirus type-1 glycoproteins: use of monoclonal antibodies to identify and characterize functional epitopes" Virology (1985) 144:216-227. van Drunen Littel-van den Hurk et al., "Polypeptide specificity of the antibody response after primary and recurrent infection with bovine herpesvirus 1" J. Clin. Microbiol. (1986) 23:274-282. van Drunen Littel-van den Hurk et al., "Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virus" J. Virol. (1989) 63:2159-2168. van Drunen Littel-van den Hurk et al., "Expression of bovine herpesvirus 1 glycoprotein gIV by recombinant baculovirus and analysis of its immunogenic properties" J. Virol. (1991) 65:263-271.
Patent History
Patent number: 5858989
Type: Grant
Filed: Jul 10, 1996
Date of Patent: Jan 12, 1999
Assignee: University of Saskatchewan (Saskatchewan)
Inventors: Lorne Babiuk (Saskatoon), Sylvia van der Hurk (Saskatoon), Tim Zamb (Saskatoon), David Fitzpatrick (Subiaco)
Primary Examiner: Thomas M. Cunningham
Law Firm: Morrison & Foerster, LLP
Application Number: 8/682,847
Classifications
Current U.S. Class: 514/44; 424/1851; 424/2291; 435/693; Proteins, I.e., More Than 100 Amino Acid Residues (530/350); Glycoprotein, E.g., Mucins, Proteoglycans, Etc. (530/395); 536/2372
International Classification: A61K 4800; A61K 39245; C12N 1538; C07K 1403;